InvestorsHub Logo
Followers 87
Posts 6564
Boards Moderated 1
Alias Born 09/18/2009

Re: pandb5298 post# 36593

Monday, 07/04/2022 8:03:16 PM

Monday, July 04, 2022 8:03:16 PM

Post# of 42514
My single, open sell order, which expires on the 20th, is for a small portion of my shares in the $2B market cap level. I'd like to see the pre-market bid run past that and get a better fill.

I want to see how much appetite there is between the US and foreign governments for their national stockpile orders to treat hospitalized Covid patients. Sotrovimab had stockpile orders for hundreds of thousands of treatments, just for the US govt, and that mAb is proving ineffective for certain omicron variants, or for hypoxic patients. Altogether, they had purchase agreements for 1.7M treatments.

https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-united-states-government-agreement-to-purchase-additional-supply-of-sotrovimab/

I'd like to see Humanigen capture and extend that market, as only we are positioned to do.

The Wainwright analyst had a share price projection for VIR/GSK of over $200 per share because of these sotrovimab purchase agreements.